Aetna and Anthem announced that they will offer expanded coverage of Novartis’ $2.1 million treatment for spinal muscular atrophy, Zolgensma, reversing an earlier decision to cover the treatment only for children younger than nine months old, Business Insider reports.
According to the report, the insurers will now cover children up to 2 years old.
“While the data on Zolgensma is limited, emerging information, expert opinions and the promise of the medication have led us to reconsider our approach,” an Aetna spokesperson tells Business Insider. “We are broadening our coverage to fully align with the FDA-approved criteria for treatment … .”
To read the full report on Business Insider, click here.